169 related articles for article (PubMed ID: 20811698)
1. Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Inamoto T; Ibuki N; Ubai T; Kotake Y; Takahara K; Kiyama S; Nomi H; Uehara H; Komura K; Yamamoto K; Narumi Y; Katsuoka Y
Int J Oncol; 2010 Oct; 37(4):773-85. PubMed ID: 20811698
[TBL] [Abstract][Full Text] [Related]
2. Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen).
Azuma H; Inamoto T; Takahara K; Nomi H; Uehara H; Komura K; Minami K; Kouno J; Kotake Y; Abe H; Takagi S; Yamamoto K; Narumi Y; Kiyama S
Int J Oncol; 2013 Jul; 43(1):79-87. PubMed ID: 23624911
[TBL] [Abstract][Full Text] [Related]
3. Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer.
Azuma H; Inamoto T; Ibuki N; Ubai T; Kotake Y; Takahara K; Kiyama S; Nomi H; Uehara H; Komura K; Yamamoto K; Narumi Y; Katsuoka Y
Int J Oncol; 2011 Jan; 38(1):13-24. PubMed ID: 21109921
[TBL] [Abstract][Full Text] [Related]
4. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
[TBL] [Abstract][Full Text] [Related]
5. A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen).
Azuma H; Inamoto T; Takahara K; Nomi H; Hirano H; Uehara H; Komura K; Minami K; Kouno J; Kotake Y; Abe H; Takagi S; Ibuki N; Yamamoto K; Narumi Y; Kiyama S
Int J Oncol; 2013 Oct; 43(4):1087-94. PubMed ID: 23934264
[TBL] [Abstract][Full Text] [Related]
6. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.
Azuma H; Inamoto T; Takahara K; Nomi H; Hirano H; Ibuki N; Uehara H; Komura K; Minami K; Uchimoto T; Saito K; Takai T; Tanda N; Yamamoto K; Narumi Y; Kiyama S
Int J Oncol; 2014 Jun; 44(6):1895-903. PubMed ID: 24728124
[TBL] [Abstract][Full Text] [Related]
7. Novel bladder preservation therapy with Osaka Medical College regimen.
Azuma H; Inamoto T; Takahara K; Nomi H; Hirano H; Ibuki N; Uehara H; Komura K; Minami K; Uchimoto T; Saito K; Takai T; Tanda N; Yamamoto K; Narumi Y; Kiyama S
J Urol; 2015 Feb; 193(2):443-50. PubMed ID: 25167990
[TBL] [Abstract][Full Text] [Related]
8. Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.
Azuma H; Inamoto T; Takahara K; Ibuki N; Nomi H; Komura K; Uehara H; Minami K; Yamamoto K; Narumi Y
Int J Oncol; 2019 Jan; 54(1):167-176. PubMed ID: 30387836
[TBL] [Abstract][Full Text] [Related]
9. Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.
Azuma H; Kotake Y; Yamamoto K; Sakamoto T; Kiyama S; Ubai T; Inamoto T; Takahara K; Matsuki M; Segawa N; Shibahara N; Katsuoka Y
Am J Clin Oncol; 2008 Feb; 31(1):11-21. PubMed ID: 18376222
[TBL] [Abstract][Full Text] [Related]
10. Treatment Results of Radiotherapy Combined with Balloon-occluded Arterial Infusion Chemotherapy for Invasive Bladder Cancer.
Yoshioka H; Shimbo T; Yoshida K; Yoshikawa N; Uesugi Y; Yamamoto K; Azuma H; Narumi Y
Anticancer Res; 2016 Feb; 36(2):731-6. PubMed ID: 26851031
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
Cognetti F; Ruggeri EM; Felici A; Gallucci M; Muto G; Pollera CF; Massidda B; Rubagotti A; Giannarelli D; Boccardo F;
Ann Oncol; 2012 Mar; 23(3):695-700. PubMed ID: 21859900
[TBL] [Abstract][Full Text] [Related]
13. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
[TBL] [Abstract][Full Text] [Related]
15. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Feng YH; Shen KH; Huang KH; Tzeng WS; Li CF; Lin KL
Clin Genitourin Cancer; 2016 Feb; 14(1):e67-74. PubMed ID: 26428609
[TBL] [Abstract][Full Text] [Related]
16. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Coen JJ; Zhang P; Saylor PJ; Lee CT; Wu CL; Parker W; Lautenschlaeger T; Zietman AL; Efstathiou JA; Jani AB; Kucuk O; Souhami L; Rodgers JP; Sandler HM; Shipley WU
J Clin Oncol; 2019 Jan; 37(1):44-51. PubMed ID: 30433852
[TBL] [Abstract][Full Text] [Related]
17. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Tunio MA; Hashmi A; Rafi M; Qayyum A; Masood R
J Pak Med Assoc; 2011 Jan; 61(1):6-10. PubMed ID: 22368893
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
19. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
